BRPI0908859A2 - composição farmacêutica estabilizada de líquído único contedo docetaxel - Google Patents

composição farmacêutica estabilizada de líquído único contedo docetaxel

Info

Publication number
BRPI0908859A2
BRPI0908859A2 BRPI0908859A BRPI0908859A BRPI0908859A2 BR PI0908859 A2 BRPI0908859 A2 BR PI0908859A2 BR PI0908859 A BRPI0908859 A BR PI0908859A BR PI0908859 A BRPI0908859 A BR PI0908859A BR PI0908859 A2 BRPI0908859 A2 BR PI0908859A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
stabilized liquid
docetaxel single
content stabilized
Prior art date
Application number
BRPI0908859A
Other languages
English (en)
Inventor
Cha Bong-Jin
Won Dong-Han
Kim Jeong-Hoon
Yoo Moo-Hi
Jang Sun-Woo
Original Assignee
Dong-A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41016586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908859(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong-A Pharm Co Ltd filed Critical Dong-A Pharm Co Ltd
Publication of BRPI0908859A2 publication Critical patent/BRPI0908859A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0908859A 2008-02-29 2009-02-26 composição farmacêutica estabilizada de líquído único contedo docetaxel BRPI0908859A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080019179A KR101053780B1 (ko) 2008-02-29 2008-02-29 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
PCT/KR2009/000911 WO2009107983A2 (ko) 2008-02-29 2009-02-26 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물

Publications (1)

Publication Number Publication Date
BRPI0908859A2 true BRPI0908859A2 (pt) 2017-06-06

Family

ID=41016586

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908859A BRPI0908859A2 (pt) 2008-02-29 2009-02-26 composição farmacêutica estabilizada de líquído único contedo docetaxel

Country Status (14)

Country Link
US (1) US20100267818A1 (pt)
JP (1) JP5552438B2 (pt)
KR (1) KR101053780B1 (pt)
CN (1) CN101959501B (pt)
AU (1) AU2009217927B2 (pt)
BR (1) BRPI0908859A2 (pt)
CA (1) CA2714942C (pt)
MX (1) MX2010009031A (pt)
MY (1) MY152013A (pt)
NZ (1) NZ587578A (pt)
RU (1) RU2478370C2 (pt)
TR (1) TR201005726T2 (pt)
WO (1) WO2009107983A2 (pt)
ZA (1) ZA201004462B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185389A1 (en) * 2010-05-03 2012-12-28 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012161520A2 (ko) * 2011-05-23 2012-11-29 에스케이케미칼 주식회사 도세탁셀을 함유하는 액상 주사용 조성물
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
JP5847942B2 (ja) * 2012-07-19 2016-01-27 富士フイルム株式会社 タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN103040739B (zh) * 2013-01-11 2014-07-23 罗诚 一种含有多西他赛化合物的药物组合物
JP6124633B2 (ja) * 2013-03-18 2017-05-10 ダイト株式会社 安定なドセタキセル注射剤
KR20140147336A (ko) * 2013-06-19 2014-12-30 에스케이케미칼주식회사 도세탁셀을 함유하는 액상 주사용 조성물
CN103432109B (zh) * 2013-09-01 2015-09-23 吴静 紫杉醇的药物组合物
CN104546694A (zh) * 2013-10-15 2015-04-29 悦康药业集团有限公司 一种多西他赛注射液及其制备方法
TWI752750B (zh) * 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN105395540A (zh) * 2015-12-01 2016-03-16 海南通用康力制药有限公司 一种多西他赛注射液及其制备方法
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
KR102401546B1 (ko) * 2020-03-25 2022-05-27 주식회사 보령 탁산, 이의 약학적으로 허용되는 염, 또는 그의 수화물을 함유하는 안정성이 향상된 신규 약제학적 제형
US20230364172A1 (en) * 2022-05-14 2023-11-16 Syncotrance, LLC Modulation of solubility, palatability, absorption, and bioavailability of mitragyna speciosa-derived compounds for oral and buccal delivery

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
AU724842B2 (en) * 1995-12-21 2000-09-28 Genelabs Technologies, Inc. Taxane composition and method
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
CZ299931B6 (cs) * 2000-01-05 2008-12-29 Neurim Pharmaceuticals (1991) Ltd. Prípravek na lécbu rezistence vuci antihypertenzivum a podobných stavu a jeho použití
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
CA2434641A1 (en) * 2001-01-18 2002-08-22 Pharmacia And Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
JP2005225818A (ja) * 2004-02-13 2005-08-25 Otsuka Pharmaceut Factory Inc パクリタキセル又はドセタキセルの医薬組成物
BRPI0608173A2 (pt) * 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
JP2008543789A (ja) * 2005-06-17 2008-12-04 ホスピラ オーストラリア ピーティーワイ エルティーディー ドセタキセルの液体薬学的処方物
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
KR100995390B1 (ko) * 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CA2649335A1 (en) * 2006-05-03 2007-11-08 I.Q.A., A.S. Pharmaceutical composition containing a taxane derivative, destined for the preparation of an infusion solution, method of preparation thereof and use thereof
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
CA2686225A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80

Also Published As

Publication number Publication date
CN101959501B (zh) 2012-08-29
JP5552438B2 (ja) 2014-07-16
WO2009107983A2 (ko) 2009-09-03
CA2714942A1 (en) 2009-09-03
WO2009107983A3 (ko) 2009-12-03
KR20090093581A (ko) 2009-09-02
KR101053780B1 (ko) 2011-08-02
RU2010139958A (ru) 2012-04-10
MX2010009031A (es) 2010-09-10
CN101959501A (zh) 2011-01-26
AU2009217927A1 (en) 2009-09-03
US20100267818A1 (en) 2010-10-21
NZ587578A (en) 2012-08-31
ZA201004462B (en) 2011-04-28
TR201005726T2 (tr) 2011-10-21
CA2714942C (en) 2014-06-17
RU2478370C2 (ru) 2013-04-10
AU2009217927B2 (en) 2012-06-07
JP2011513299A (ja) 2011-04-28
MY152013A (en) 2014-08-15

Similar Documents

Publication Publication Date Title
BRPI0908859A2 (pt) composição farmacêutica estabilizada de líquído único contedo docetaxel
LTPA2018014I1 (lt) Farmacinė kompozicija 514
LTC2140867I2 (lt) Farmacinė kompozicija
BRPI0910515A2 (pt) composição líquida
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
BRPI0721651A2 (pt) Composição farmacêutica
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI0821474A2 (pt) formulação farmacêutica líquida estável
BRPI0920521A2 (pt) combinação farmacêutica
EP3329912C0 (en) LIQUID COMPOSITION
PT2475352E (pt) Composição contendo palmitoiletanolamida ultramicronizada
BRPI0715712A2 (pt) Composição farmacêutica
DK2285357T3 (da) Farmaceutisk sammensætning omfattende brivaracetam
BRPI0719393A2 (pt) Composição farmacêutica
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI1015939A2 (pt) composição farmacêutica
BRPI0809661A2 (pt) Composição farmacêutica estabilizada contendo pregabalina
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DK2120884T3 (da) Farmaceutisk sammensætning
EP2236149A4 (en) MEDICAL COMPOSITION
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0910901A2 (pt) composição farmacêutica com bisfosfonato
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.